BOLT - Bolt Biotherapeutics, Inc.

4.3
-0.050   -1.163%

Share volume: 10,302
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.26%

PREVIOUS CLOSE
CHG
CHG%
$4.35
-0.05
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
38%
Profitability 35%
Dept financing 29%
Liquidity 50%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-5.08%
1 Month
-18.10%
3 Months
-19.93%
6 Months
-16.50%
1 Year
886.24%
2 Year
834.78%
Key data
Stock price
$4.30
P/E Ratio 
0.00
DAY RANGE
$4.26 - $4.50
EPS 
-$4.42
52 WEEK RANGE
$0.26 - $7.35
52 WEEK CHANGE
$943.69
MARKET CAP 
10.211 M
YIELD 
N/A
SHARES OUTSTANDING 
1.919 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-13-2025
BETA 
0.00
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
$22,389
AVERAGE 30 VOLUME 
$29,936
Company detail
CEO: Randall C. Schatzman
Region: US
Website: boltbio.com
Employees: 90
IPO year: 2021
Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Bolt Biotherapeutics, Inc. engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors.

Recent news